Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.55 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635920 | 0.85 | BRD4 (0.51) | MTNR1AMTNR1BACSS2NPC1MAPT | |
| SCHEMBL2018097 | 0.85 | HTT (0.59) | ACSS2HTTMAPTRAB9A | |
| SCHEMBL2018295 | 0.84 | HTT (0.52) | ACSS2HTTMAPT | |
| SCHEMBL20191187 | 0.82 | HTT (0.51) | ACSS2HTT | |
| SCHEMBL2020612 | 0.80 | ACSS2 (0.56) | MTNR1AMTNR1BACSS2TDP1S1PR1 | |
| SCHEMBL4036510 | 0.80 | S1PR1 (0.52) | ACSS2HTTS1PR1CYP3A4CYP2C19 | |
| SCHEMBL2018438 | 0.79 | SCNN1A (0.44) | MTNR1AMTNR1BACSS2HTTS1PR1 | |
| SCHEMBL16176419 | 0.78 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL16406373 | 0.78 | ACSS2 (0.53) | MTNR1AMTNR1BACSS2TDP1S1PR1 | |
| SCHEMBL12635707 | 0.77 | PPARG (0.45) | MTNR1AMTNR1BACSS2HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3794002-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| EP-3544981-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018096325-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | NHERF1, SCNN1B, SCNN1A | MTNR1A 1107/4885MTNR1B 1679/4885ACSS2 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.